Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05522231

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy as second-line treatment for locally advanced or metastatic renal cell carcinoma. The second part is a fruquintinib monotherapy factorial cohort study to evaluate the efficacy and safety of fruquintinib monotherapy as for second-line treatment of locally advanced or metastatic renal cell carcinoma.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Advanced Renal Cell Carcinoma

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Loading trial locations.

About this study

The target populations for this study were patients with histologically or cytologically confirmed, locally advanced/ metastatic renal cell carcinoma who progressed during or after or intolerant to previous first-line VEGFR-TKI therapy.

A total of about 249-264 patients are planned to be enrolled in the study, among whom about 234 patients are planned to be enrolled in the first part. The patients who are successfully enrolled will be randomly assigned into the investigational arm or the control arm in a 1:1 ratio. The enrollment of part 2 will be started after that of part 1 is completed. About 15~30 patients are planned to be enrolled in the second part. The patients who are successfully enrolled will receive fruquintinib monotherapy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 to 75 (inclusive) years of age on the date when ICF was signed;
  • Histologically or cytologically confirmed renal clear cell carcinoma;
  • Patients with locally advanced/metastatic renal carcinoma;
  • Patients with renal carcinoma who progressed during or after or intolerant to previous first-line VEGFR-TKI therapy for advanced/metastatic disease;
  • At least 1 measurable lesion according to RECIST 1.1;
  • ECOG PS of 0 or 1;
  • Adequate organ function.

Exclusion criteria

  • Had previously received therapy targeting immune modulatory receptors or related pathways (including but not limited to therapy targeting PD-1, CTLA-4, IDO, PD-L1, LAG-3, TIGIT, IL-2R and GITR, etc, but excluding related cytokine therapy such as IL2), excluding patients who had received immunotherapy such as anti-PD- (L) 1 antibody in adjuvant/neoadjuvant therapy setting and did not progress within 6 months after discontinuation;
  • Receiving approved systemic anti-tumor therapy within 2 weeks prior to the first dose;
  • Toxicities caused by prior anti-tumor therapy before the first dose that did not recover to Grade 0 or 1 per the NCI CTCAE v5.0 or to the level specified in the enrollment criteria (excluding alopecia and peripheral neurotoxicity ≤ CTCAE Grade 2);
  • Immunosuppression medication within 4 weeks prior to randomization;
  • Patients with active autoimmune or inflammatory diseases;
  • Known central nervous system (CNS) metastasis;
  • History of pneumonitis requiring corticosteroid therapy, or history of or current interstitial lung disease, or current active pulmonary infection, etc.;
  • Toxicities caused by prior anti-tumor therapy before the first dose that did not recover to Grade 0 or 1 per the National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) v5.0 or to the level specified in the enrollment criteria (excluding alopecia and peripheral neurotoxicities ≤CTCAE Grade 2 caused by platinum-based chemotherapy; thyroid dysfunction with stable disease control after symptomatic treatment);
  • Human Immunodeficiency Virus (HIV) Infection (HIV 1/2 Antibody positive);
  • Uncontrolled hypertension despite standard therapy;
  • Patient with evidence or history of haemorrhagic tendency within 2 months prior to the first dose, regardless of severity.

Treatment and study plan

fruquintinib+sintilimab

Drug

fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.

Other names: HMPL-013 + IBI308

axitinib / everolimus

Drug

axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion based on clinical; everolimus, 10 mg, QD, PO, 3 weeks/cycle.

FRUQUINTINIB

Drug

fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.

Other names: HMPL-013

Primary outcomes

  1. Progression free survival (PFS) in Part I

    Time frame: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months.

    PFS per RECIST 1.1 by BIRC

  2. Objective response rate (ORR) in Part II

    Time frame: Time from the date of first treatment administration until disease progression or the introduction of a new treatment, assessed up to 20 months.

    ORR per RECIST 1.1 by investigator

Secondary outcomes

  1. PFS

    Time frame: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months.

    PFS per RECIST 1.1

  2. Safety in Part I

    Time frame: Through study completion, assessed up to 20 months.

    Severity and Incidence of Adverse event (AEs) and findings in Laboratory test, vital signs, 12-lead Electrocardiogram (ECG), etc. in Part I

  3. Quality of life in Part I

    Time frame: Through study completion, assessed up to 20 months.

    Quality of life questionnaire analysis in Part I

  4. Safety in Part II

    Time frame: Through study completion, assessed up to 20 months.

    Severity and incidence of AEs and findings in such as Laboratory test, vital signs, 12-lead ECG, etc. in Part II.

  5. Disease control rate (DCR)

    Time frame: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months.

    PFS per RECIST 1.1

  6. ORR

    Time frame: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months.

    ORR per RECIST 1.1

  7. Duration of response (DoR)

    Time frame: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months.

    DoR per RECIST 1.1

  8. Time to Response (TTR)

    Time frame: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months.

    TTR per RECIST 1.1

  9. OS

    Time frame: Time from date of randomization until the date of death from any cause, assessed up to 20 months.

    OS

Sponsors and collaborators

Lead sponsor

Hutchmed

Industry

Registry information

Official study title

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Fruquintinib in Combination With Sintilimab Versus Axitinib or Everolimus as Second-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (FRUSICA-2)

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Aug 30, 2022
Registry last updated
Jan 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.